JP Morgan Chase’s DexCom DXCM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.4M | Sell |
55,000
-23,700
| -30% | -$1.65M | ﹤0.01% | 3675 |
|
|
2025
Q4 | $5.22M | Buy |
78,700
+52,900
| +205% | +$3.42M | ﹤0.01% | 3268 |
|
|
2025
Q3 | $1.74M | Buy |
25,800
+23,700
| +1,129% | +$1.88M | ﹤0.01% | 4182 |
|
|
2025
Q2 | $183K | Buy |
+2,100
| New | +$165K | ﹤0.01% | 5280 |
|
|
2025
Q1 | – | Sell |
-64,700
| Closed | -$5.03M | – | 7395 |
|
|
2024
Q4 | $5.03M | Buy |
64,700
+52,100
| +413% | +$3.86M | ﹤0.01% | 3343 |
|
|
2024
Q3 | $845K | Sell |
12,600
-23,400
| -65% | -$1.92M | ﹤0.01% | 4577 |
|
|
2024
Q2 | $4.08M | Sell |
36,000
-4,000
| -10% | -$506K | ﹤0.01% | 3194 |
|
|
2024
Q1 | $5.55M | Sell |
40,000
-69,900
| -64% | -$8.79M | ﹤0.01% | 3013 |
|
|
2023
Q4 | $13.6M | Buy |
109,900
+62,200
| +130% | +$6.35M | ﹤0.01% | 2175 |
|
|
2023
Q3 | $4.45M | Buy |
+47,700
| New | +$5.38M | ﹤0.01% | 2919 |
|
|
2023
Q1 | – | Sell |
-407,900
| Closed | -$46.2M | – | 6813 |
|
|
2022
Q4 | $46.2M | Buy |
407,900
+187,900
| +85% | +$20.6M | 0.01% | 1157 |
|
|
2022
Q3 | $17.7M | Buy |
+220,000
| New | +$18.6M | ﹤0.01% | 1663 |
|
|
2022
Q1 | – | Sell |
-120,000
| Closed | -$16.1M | – | 6683 |
|
|
2021
Q4 | $16.1M | Buy |
+120,000
| New | +$17.2M | ﹤0.01% | 2005 |
|
|
2021
Q1 | – | Sell |
-136,000
| Closed | -$12.6M | – | 6120 |
|
|
2020
Q4 | $12.6M | Buy |
+136,000
| New | +$12.1M | ﹤0.01% | 2024 |
|
|
2020
Q1 | – | Sell |
-200,000
| Closed | -$10.9M | – | 5379 |
|
|
2019
Q4 | $10.9M | Buy |
+200,000
| New | +$9.49M | ﹤0.01% | 2042 |
|
|
2019
Q1 | – | Sell |
-140,000
| Closed | -$4.19M | – | 5822 |
|
|
2018
Q4 | $4.19M | Buy |
+140,000
| New | +$4.44M | ﹤0.01% | 2721 |
|
|
2018
Q3 | – | Sell |
-160,000
| Closed | -$3.8M | – | 5698 |
|
|
2018
Q2 | $3.8M | Buy |
+160,000
| New | +$3.39M | ﹤0.01% | 2901 |
|
|
2017
Q3 | – | Sell |
-26,000,000
| Closed | -$475M | – | 5005 |
|
|
2017
Q2 | $475M | Hold |
26,000,000
| – | – | 0.11% | 202 |
|
|
2017
Q1 | $551M | Hold |
26,000,000
| – | – | 0.13% | 181 |
|
|
2016
Q4 | $388M | Hold |
26,000,000
| – | – | 0.09% | 228 |
|
|
2016
Q3 | $570M | Buy |
+26,000,000
| New | +$579M | 0.14% | 167 |
|
|
2015
Q2 | – | Sell |
-132,000
| Closed | -$2.06M | – | 4048 |
|
|
2015
Q1 | $2.06M | Buy |
+132,000
| New | +$1.99M | ﹤0.01% | 2851 |
|
Other funds holding DXCM
VCM
VPM
JP Morgan Chase's DXCM Position: Q1 2026 in Review
JP Morgan Chase reduced its DexCom (DXCM) stake by 3.5% in Q1 2026, selling an estimated $15.1M and leaving 5,999,470 shares worth $371M. The position accounts for 0.02% of the portfolio, ranked #491.
JP Morgan Chase first reported a position in DXCM in Q2 2013 and has held it in 50 quarters since. The position peaked at $1.64B in Q3 2021. 957 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.
- JP Morgan Chase held 5,999,470 shares of DexCom worth $371M as of Q1 2026.
- JP Morgan Chase sold 216,931 DexCom shares in Q1 2026, an estimated $15.1M.
- DexCom made up 0.02% of JP Morgan Chase's portfolio in Q1 2026, its #491 holding.
- JP Morgan Chase first reported a position in DexCom in Q2 2013 and has held it in 50 quarters since.
- JP Morgan Chase's DexCom position peaked at $1.64B in Q3 2021.
- 957 funds tracked by Wall St. Rank held DexCom as of Q1 2026.
Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.